Status:
COMPLETED
Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This phase I trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 when given together with gemcitabine hydrochloride in treating patients with advanced solid tumors....
Detailed Description
PRIMARY OBJECTIVES: I. To determine the safety profile and establish the maximum-tolerated dose and recommended phase II dose of gamma-secretase inhibitor RO4929097 in combination with gemcitabine hy...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Meets one of the following sets of criteria:
- Histologically and/or cytologically confirmed solid malignancy
- Metastatic or unresectable disease
- Disease for which standard curative or palliative measures do not exist or are no longer effective
- Histologically and/or cytologically confirmed adenocarcinoma of the pancreas (for patients in the expansion cohort)
- Locally advanced or metastatic disease
- No prior chemotherapy for advanced disease
- Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan
- No known brain metastases
- ECOG performance status (PS) 0-1 (Karnofsky PS 60-100%)
- Life expectancy \> 12 weeks
- Hemoglobin ≥ 90 g/L (or ≥ 9 g/dL)
- Leukocytes ≥ 3,000/mm\^3
- ANC ≥ 1,500/mm\^3
- Platelet count ≥ 100,000/mm\^3
- Total bilirubin ≤ 1.25 times upper limit of normal (ULN)
- AST/ALT ≤ 1.5 times ULN
- Serum creatinine =\< ULN OR creatinine clearance ≥ 60 mL/min
- No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, or hypokalemia, defined as less than the lower limit of normal despite adequate electrolyte supplementation
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use two forms of adequate contraception (i.e., barrier contraception and one other method of contraception) for ≥ 4 weeks before, during, and for ≥ 12 months after completion of study treatment
- Able to swallow medication
- No malabsorption syndrome or other condition that would interfere with intestinal absorption
- No uncontrolled concurrent illness including, but not limited to, any of the following:
- Ongoing or active infection
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia other than chronic, stable atrial fibrillation
- Psychiatric illness or social situations that would limit compliance with study requirements
- No baseline QTc \> 450 msec (for male patients) or \> 470 msec (for female patients)
- No history of risk factors for QT interval prolongation including, but not limited to, a family or personal history of any of the following:
- Long QT syndrome
- Recurrent syncope without known etiology
- Sudden unexpected death
- No history of torsade de pointes or other significant cardiac arrhythmias or the need for concomitant meds with known potential to prolong QT interval or antiarrhythmics
- No diarrhea ≥ grade 2 not under control with standard anti-diarrhea medications
- No serologic positivity for hepatitis A, B, or C
- No history of liver disease or other forms of hepatitis or cirrhosis
- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to gamma-secretase inhibitor RO4929097 or to gemcitabine hydrochloride
- Female patients may not donate ova during or after completion of study treatment
- Male patients may not donate sperm during and for ≥ 12 months after completion of study treatment
- Patients may not donate blood during and for ≥ 12 months after completion of study treatment
- No other concurrent investigational or commercial agents or therapies administered with the intent to treat the patient's malignancy
- Any number of prior therapies allowed
- No prior therapy with a Notch inhibitor
- At least 4 weeks since prior radiotherapy, chemotherapy, or systemic therapy (6 weeks if the last regimen included nitrosourea or mitomycin C) and recovered
- Exceptions may be made for low-dose, non-myelosuppressive radiotherapy for symptomatic palliation
- Patients in the expansion cohort must meet the following criteria:
- No prior chemotherapy for advanced disease except for fluorouracil (with or without folinic acid) or gemcitabine hydrochloride given concurrently with radiotherapy as a "radiosensitizer"
- At least 6 months since prior adjuvant gemcitabine hydrochloride
- Prior radiotherapy for the management of local disease allowed provided \> 4 weeks have elapsed since the last radiation treatment and all toxicities have resolved
- Patients who have had radiotherapy to their sole site of disease are eligible provided they have documented progression of that lesion before study registration
- Recovered from side effects of previous systemic anticancer therapy to ≤ CTCAE grade 2
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No concurrent medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin®)
- No concurrent medications with known potential to prolong QT interval
- No concurrent medications that are strong inducers/inhibitors or substrates of CYP3A4
- No concurrent medications or food that may interfere with the metabolism of gamma-secretase inhibitor RO4929097, including ketoconazole and grapefruit or grapefruit juice
- No other concurrent investigational agents
Exclusion
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT01145456
Start Date
June 1 2010
Last Update
February 24 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada, L8V 5C2
2
University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9